Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma

Secreted Protein Acid and Rich in Cysteine (SPARC) is an extracellular glycoprotein secreted by fibroblasts and osteoblasts in normal tissues. SPARC overexpression occurs in multiple tumors including pancreatic ductal adenocarcinoma (PDAC) and may predict favorable response to nab-paclitaxel. The pr...

Full description

Bibliographic Details
Main Authors:	Christopher Hartley, Daniel Rowan, Xiuxu Chen, Luisa Gomez-Arellano, Anna Marie West, Kiyoko Oshima, Alexander Craig Mackinnon
Format:	Article
Language:	English
Published:	Elsevier 2020-08-01
Series:	Practical Laboratory Medicine
Subjects:	SPARC Pancreatic cancer Neoadjuvant therapy Adjuvant therapy Immunohistochemistry Digital image analysis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352551719301015

Similar Items

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
by: Hyung Sun Kim, et al.
Published: (2021-02-01)

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
by: Fuyuhiko Motoi, et al.
Published: (2020-03-01)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
by: Morgan Bonds, et al.
Published: (2019-08-01)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
by: Christina Hadzitheodorou, et al.
Published: (2017-04-01)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
by: Qiancheng Hu, et al.
Published: (2019-07-01)

Current status and perspectives of neoadjuvant therapy for pancreatic cancer
by: LIANG Tingbo
Published: (2019-05-01)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
by: Hosein Peter J, et al.
Published: (2012-05-01)

Emphasis on neoadjuvant therapy for “resectable” pancreatic cancer
by: LIU Chang
Published: (2015-05-01)

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis
by: Saber Amin, et al.
Published: (2020-06-01)

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
by: Akhil Chawla, et al.
Published: (2019-10-01)

Perception versus reality: A National Cohort Analysis of the surgery‐first approach for resectable pancreatic cancer
by: John R. Bergquist, et al.
Published: (2021-09-01)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
by: Bathiya Ratnayake, et al.
Published: (2020-07-01)

The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy
by: Hironobu Suto, et al.
Published: (2019-12-01)

Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma
by: Shin Hye Hwang, et al.
Published: (2021-03-01)

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
by: Ester Oneda, et al.
Published: (2019-11-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients
by: Mashaal Dhir, et al.
Published: (2017-10-01)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
by: Xu Yaping, et al.
Published: (2012-08-01)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
by: Nathalie Rosumeck, et al.
Published: (2021-01-01)

Pancreatic Ductal Adenocarcinoma: Relating Biomechanics and Prognosis
by: Benjamin M. MacCurtain, et al.
Published: (2021-06-01)

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer
by: Liqiong Yang, et al.
Published: (2021-08-01)

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
by: Stefan Heinrich, et al.
Published: (2019-07-01)

Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy—Arterial Resection, Arterial Divestment and Total Pancreatectomy
by: Yosuke Inoue, et al.
Published: (2021-04-01)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
by: Naoki Mita, et al.
Published: (2021-06-01)

Evolution of dental tissue mineralization: an analysis of the jawed vertebrate SPARC and SPARC-L families
by: Sébastien Enault, et al.
Published: (2018-08-01)

Is Margin Status Less Prognostic After Neoadjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma?
by: Callery, M.P, et al.
Published: (2022)

NEOADJUVANT AND ADJUVANT CHEMOHORMONAL THERAPY IN PATIENTS WITH HIGH-RISK AND VERY HIGH-RISK PROSTATE CANCER: OUR EXPERIENCE
by: T. V. Ustinova, et al.
Published: (2018-10-01)

Neoadjuvant Therapy in Patients with Pancreatic Cancer: A Disappointing Therapeutic Approach?
by: Robert Grutzmann, et al.
Published: (2011-05-01)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
by: Ren X, et al.
Published: (2019-01-01)

Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021
by: Anthony Turpin, et al.
Published: (2020-12-01)

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
by: Salvatore Paiella, et al.
Published: (2021-02-01)

Effect of neoadjuvant therapy on breast cancer biomarker profile
by: Laura Rey-Vargas, et al.
Published: (2020-07-01)

Change of SPARC expression after chemotherapy in gastric cancer
by: Yong-Yin Gao, et al.
Published: (2015-03-01)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
by: Kamil D. Dalgatov, et al.
Published: (2021-08-01)

Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma
by: Margareta Heby, et al.
Published: (2018-03-01)

Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
by: Stefan Heinrich, et al.
Published: (2017-07-01)

A PARADIGM SHIFT IN THE TREATMENT OF PATIENTS WITH RESECTABLE PANCREATIC CANCER
by: E. Yu. Antonova, et al.
Published: (2020-07-01)

Role of stromal SPARC in PDAC tumorigenesis and drug delivery
by: Ramu, Iswarya
Published: (2019)

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
by: Dingyuan Hu, et al.
Published: (2019-02-01)

Features of immunophenotype of pancreatic ductal adenocarcinoma
by: A. V. Evseyev
Published: (2014-12-01)